Preferred Label : Anti-PD-1/TGFbRII Fusion Protein LBL-015;
NCIt synonyms : Anti-PD-1/TGF-beta Receptor II Bispecific Fusion Protein LBL-015; Bispecific Fusion Protein LBL-015;
NCIt definition : A tetravalent bispecific fusion protein targeting both the human negative immunoregulatory
checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human
transforming growth factor beta (TGF-beta; TGFb), with potential immune checkpoint
modulating and antineoplastic activities. Upon administration, anti-PD-1/TGF-beta
receptor II (TGFbRII) fusion protein LBL-015 targets and binds to PD-1 and TGF-beta
and prevents the activation of PD-1 and TGF-beta-mediated signaling pathways in the
tumor microenvironment (TME). This abrogates the PD-1- and TGFb-mediated immunosuppression
in the TME, increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities,
and inhibits tumor cell proliferation in susceptible tumor cells. PD-1, an inhibitory
receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated
T-lymphocyte; it functions as an immune checkpoint that negatively regulates T-cell
activation and effector function when activated by its ligands and plays an important
role in tumor evasion from host immunity. TGF-beta, a pro-inflammatory mediator, is
upregulated in certain types of cancers and is involved in cancer cell proliferation,
tumor progression, migration and invasion, and the suppression of the immune response.;
Molecule name : LBL 015; LBL-015;
NCI Metathesaurus CUI : CL1773735;
Origin ID : C185425;
UMLS CUI : C5666994;
Semantic type(s)
- concept_is_in_subset
- has_target
